Karyopharm Therapeutics reported a strong Q3 2025, with total revenue rising 13% year-over-year to $44 million, driven by solid performance from its XPOVIO product line and significant advancements in clinical development.

• Completed enrollment in the pivotal Phase III SENTRY trial for frontline myelofibrosis, with top-line results expected in March and potential to redefine treatment standards.
• Achieved U.S. net product revenue growth of 8.5%, totaling $32 million, reflecting ongoing strength in the multiple myeloma segment.
• Secured approximately $100 million in financing, extending cash runway into Q2 2026 and supporting three core priorities: advancing clinical programs, growing the XPOVIO franchise, and maintaining financial discipline.